The best peptides for recovery research

This guide reflects our own reading of the preclinical and clinical literature that has been published up to 2026. We assign each peptide to a repair pathway on the basis of its mechanism and of the strength of its evidence base, and not on the basis of its reputation.

Recovery peptides: the essentials

• Recovery peptides act on different tissue-repair pathways from one another; mapping them according to mechanism is far more useful than drawing up rankings.
• BPC-157, TB-500, GHK-Cu, MOTS-c and CJC-1295 + ipamorelin each target a different repair variable (angiogenesis, cell migration, collagen remodelling, mitochondrial recovery, GH-axis signalling).
• None of them is an authorised medicinal product; all of them are supplied exclusively for laboratory research.
• Human data remain limited; in 2026, the bulk of the evidence still comes from rodent and in vitro models.
• Pre-filled pens set the dose directly in milligrams, so the same figure means exactly the same thing across every arm of a study.

---

The best peptides for recovery research in 2026 are chosen according to their tissue-repair mechanism, not according to rankings: BPC-157 for cytoprotection and angiogenesis, TB-500 (thymosin β4) for cell migration and systemic repair, GHK-Cu for collagen remodelling, MOTS-c for mitochondrial recovery and CJC-1295 + ipamorelin for GH-axis signalling [1][4][6][7][8][9]. Each one of them acts on a repair pathway of its own, which is why mapping by mechanism is superior to any kind of generic ranking.

None of these compounds is an authorised medicinal product; all of them are supplied exclusively for laboratory research [10]. The human data remain limited. BPC-157 and TB-500, including the popular "Wolverine stack", continue to rest above all on rodent and in vitro models, and there were still no published phase II/III randomised controlled trials in musculoskeletal conditions as of 2026 [2][5].

What this guide covers

This guide explains how recovery peptides map onto specific tissue-repair pathways, presents five compounds (BPC-157, TB-500, GHK-Cu, MOTS-c, CJC-1295/ipamorelin), covers the regulatory position in 2026 together with WADA's stance, and describes how multi-dose pen formats with a validated dose reduce variance in research work. The final section offers a decision framework to help you choose the peptide that is right for your particular variable of interest.

Featured picks: best recovery peptides for research (2026)

Recovery is a problem that involves several signalling pathways at once, so our featured recommendations are organised as best in class by repair pathway rather than as a single overall winner. Each pick is a research peptide taken from the Body Pharm catalogue, and each is supplied exclusively for laboratory and analytical purposes.

• Best overall / most complete soft-tissue mechanism: BPC-157 + TB-500 combination pen. The most requested recovery stack, which combines BPC-157's local cytoprotection and VEGF-mediated angiogenesis with TB-500's actin-driven, systemic cell migration, and in doing so covers complementary phases of tissue repair in a single pen.
• Best for mitochondrial / metabolic recovery: MOTS-c. The mitochondria-encoded peptide that activates AMPK and modulates metabolic gene expression (Lee et al., 2015), the reference tool for models of post-exertion mitochondrial fatigue and metabolic recovery.
• Best for GH-axis recovery signalling: CJC-1295 + Ipamorelin. A GHRH analogue plus a selective ghrelin mimetic, studied for the pulsatile GH/IGF-1 release that is relevant to anabolic signalling and to recovery during deep sleep.
• Best for collagen / dermal remodelling: GHK-Cu. The copper tripeptide standard for collagen synthesis and anti-inflammatory remodelling of the extracellular matrix, the natural complement to a structural-repair arm.

Read these as recommendations by pathway: the right choice is the one whose mechanism matches both the tissue and the variable in your model. The decision matrix further down the page maps each compound to its repair pathway in full detail.

What are recovery peptides? (2026 overview)

Recovery peptides are short amino-acid sequences, either synthetic or naturally occurring, that are studied in preclinical models for their effect on tissue repair, angiogenesis, cytoprotection and mitochondrial recovery, and not for any acute enhancement of performance [1][2]. They are distinct from performance peptides, such as the GH-axis secretagogues, which are used mainly for hypertrophy or for fat loss, although CJC-1295 and ipamorelin sit right on the boundary because of their indirect role in repair by way of GH/IGF-1 signalling [7].

In 2026, none of the peptides covered here (BPC-157, TB-500, GHK-Cu, MOTS-c, CJC-1295, ipamorelin) is a medicinal product that has been authorised for therapeutic use in humans [10]. They are supplied exclusively for in vitro and laboratory research, and suppliers must steer clear of any medical claims in order to comply with the regulations [10].

The current evidence base is preclinical. BPC-157 and TB-500 are the two most cited soft-tissue repair peptides in the rodent and in vitro literature, and there were no published phase II/III randomised controlled trials in human musculoskeletal conditions as of 2026 [2].

Traits that define a recovery peptide

• Mechanism-driven: it acts on a defined repair pathway (for example, angiogenesis mediated by VEGF, vascular endothelial growth factor, in the case of BPC-157, or actin sequestration in the case of TB-500) [4][11].
• Preclinical evidence base: it is supported above all by rodent and in vitro models, and not by randomised trials in humans [2].
• Not authorised: it is not an authorised medicinal product, and it can only be supplied for research purposes [10].
• Prohibited in competition by WADA, insofar as it falls into the classes of peptide hormones or growth factors [3].

For a direct, side-by-side comparison of the two most studied soft-tissue compounds, see BPC-157 vs. TB-500: recovery peptide comparison.

Decision matrix by repair pathway: which peptide for which research goal?

Mapping by mechanism is the single most useful filter when you are selecting recovery peptides. Each compound acts on a tissue-repair pathway of its own, and the wrong choice will produce null results regardless of what dose you use. The matrix below maps the six most studied recovery peptides (plus NAD+) to their main mechanism, to the tissue that has the strongest preclinical evidence behind it and to the format that Body Pharm supplies in 2026.

How to read the matrix

Read it row by row, not column by column. If you are modelling repair of the Achilles tendon, steer towards BPC-157, because tendon is the tissue with the densest preclinical signal for that particular compound [1][2], and not because BPC-157 happens to sit at the top of some generic list. If you are modelling exercise-induced mitochondrial dysfunction, steer towards MOTS-c, because the 2015 work by Lee et al. in Cell Metabolism establishes the mitochondrial AMPK pathway as its main site of action [9].

Why mapping by mechanism matters in study design

Decisions about combinations follow the very same logic. The BPC-157 + TB-500 combination is, in 2026, the most commercially requested combination in the whole research-peptide market, but no peer-reviewed study of the combination has ever been published [5], so any protocol that makes use of it has to be framed as hypothesis-driven. For a direct comparison, see BPC-157 vs. TB-500: recovery peptide comparison; for the dosing schemes once the combination has been chosen, see How to dose BPC-157 + TB-500.

BPC-157: the most studied soft-tissue repair peptide

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide that is derived from a protective sequence found in human gastric juice. It is the most cited recovery peptide in the whole preclinical literature on soft-tissue repair, because rodent models consistently show accelerated healing of tendons, ligaments and intestinal mucosa by way of the upregulation of VEGF and the modulation of the nitric oxide pathway [1][2][11].

Mechanism and preclinical evidence base

The foundational mechanistic work by Sikiric and colleagues, which is summarised in their 2018 review in Current Pharmaceutical Design, showed that BPC-157 promotes angiogenesis through the activation of VEGFR2, stabilises endothelial integrity and accelerates the reattachment of tendon to bone in rodent models of Achilles tendon transection [1][11]. Later work in rodents extended the signal to medial collateral ligament transection, to segmental colitis and to gastric ulcer models, which is why those who are modelling connective-tissue injury turn to this compound ahead of the systemic alternatives [2][11].

Data from human clinical trials remain limited in 2026. No peer-reviewed phase II or phase III trial in musculoskeletal conditions has published its results, and the reviews from 2024 and 2025 continue to describe BPC-157 as an investigational peptide that is supported mainly by rodent and in vitro data [2]. Every research protocol has to take that limit on the evidence into account from the outset.

What to check in a research-grade supply

When you are assessing BPC-157 for a tissue-repair study, there are five characteristics of the supply that matter:

• Sequence purity, verified by HPLC (high-performance liquid chromatography) at ≥98%, with the batch certificate available before shipping.
• Dose precision across repeated subcutaneous injections: a pen that sets the dose in milligrams delivers the same figure in week 1 as it does in week 8.
• Storage conditions: between 2 and 8 °C protected from light, 24 months unopened and 12 months from the first puncture, with up to 30 days at room temperature (maximum 30 °C) if no fridge is available. Bring to room temperature before injecting and do not freeze.
• Suitability of the format for the protocol: a single cartridge should cover repeated dosing across a 4-to-8-week study arm without any change of unit.
• Availability in combination, if the research design pairs BPC-157 with TB-500 for a local-plus-systemic repair signal [4][5].

Body Pharm supplies BPC-157 in the BPC-157 + TB-500 combination pen: a single 3 ml cartridge holding 32 mg in total, with 16 mg of each peptide co-dissolved. There is just one dial, and the figure you set on it is the dose of each of the two peptides, so 0.25 mg dialled means 0.25 mg of BPC-157 and 0.25 mg of TB-500. That single reading keeps the dose constant across repeated administrations, which is a substantial design advantage in any study with longitudinal variables. For a direct comparison of mechanisms, see BPC-157 vs. TB-500: recovery peptide comparison, and for protocol design once the combination has been chosen, How to dose BPC-157 + TB-500.

TB-500 (thymosin beta-4): angiogenesis and soft-tissue repair

TB-500 is a synthetic fragment of thymosin beta-4 that promotes actin polymerisation, endothelial cell migration and angiogenesis in preclinical models of both soft-tissue and cardiac repair [4]. It is the systemic-repair counterpart that the majority of researchers pair with the local cytoprotective effect of BPC-157.

Mechanism and what TB-500 actually is

TB-500 is not the full-length thymosin beta-4 molecule. It is a synthetic analogue that corresponds to the active region of the Tβ4 molecule (the sequence that contains Ac-SDKP), and it is designed to improve solubility and tissue penetration for research purposes. The mechanistic interest centres on four distinct effects:

• Actin sequestration and polymerisation, which supports the reorganisation of the cytoskeleton during cell migration towards injured tissue.
• Upregulation of VEGF signalling, which drives the angiogenic response in ischaemic or damaged muscle.
• Anti-inflammatory modulation at the site of injury, which in rodent models of cardiac and musculoskeletal injury reduces the extent of secondary tissue damage.
• Recruitment of progenitor cells towards areas where there is soft-tissue and connective-tissue damage.

The go-to review reference for these mechanisms is still the 2015 work by Goldstein and Kleinman on the biology of thymosin beta-4 in Expert Opinion on Biological Therapy [12]. Any evidence on TB-500 that was published before 2023 should be regarded as potentially out of date where trial-quality variables are concerned, because between 2024 and 2026 no registered human study reporting TB-500 results in tendon, ligament or cardiac repair has been published [4][5].

Why TB-500 is combined with BPC-157

The rationale for the combination is mechanistic complementarity, and not data from studies of the combination itself. BPC-157 acts mainly on local cytoprotection and on gastric-derived repair signalling, whereas TB-500 acts in a systemic way on angiogenesis and cell migration [4][11]. No peer-reviewed study of the combination with defined dosing and defined variables has been published, so the combination must be framed as hypothesis-driven and not as validated [5].

For the direct breakdown, see BPC-157 vs. TB-500: recovery peptide comparison, and for the protocol planning once the combination has been chosen, see How to dose BPC-157 + TB-500.

BPC-157 + TB-500: why they are combined in research

The BPC-157 + TB-500 combination is studied as a stack of complementary mechanisms, because each of the two peptides acts on a tissue-regeneration pathway of its own that the other one does not cover [4][11]. BPC-157 drives local cytoprotection and VEGF-mediated angiogenic signalling at the site of the injury, while TB-500 (a synthetic fragment of thymosin β4) acts in a systemic way on actin sequestration, on cell migration and on broader vascular remodelling [4][11].

The combined rationale, as it is framed by the professional and popular sources from 2024 to 2026, is a mechanistic one and has not been validated by any studies [5]:

• Double angiogenic coverage: BPC-157 upregulates VEGF locally; TB-500 promotes endothelial migration and capillary formation in ischaemic tissue [4][11].
• Cytoprotection plus cell migration: BPC-157 stabilises injured cells close to the lesion; TB-500 mobilises progenitor cells from the circulation towards damaged connective tissue [4][11].
• Signal from tendon and ligament repair models: the pre-2023 rodent work on Achilles tendon transection and medial collateral ligament injury describes faster fibroblast organisation with each peptide administered on its own, which is the basis of the combination hypothesis [1][4].
• Overlap in intestinal mucosa repair: BPC-157 has the densest evidence in gastric mucosa, and it is hypothesised that TB-500's systemic angiogenic effect supports enteric capillary recovery in those very same models [4][11].

As of 2026 there are no randomised trials of the combination at all, so the stack remains hypothesis-driven and has not been validated as a combination [5].

Body Pharm's combination pen format

Body Pharm's BPC-157 + TB-500 combination pen is a sealed, pre-filled multi-dose pen with a 3 ml cartridge that contains 32 mg in total: 16 mg of BPC-157 and 16 mg of TB-500, co-dissolved together. It ships discreetly within Spain, exclusively for research and analytical purposes. The dial sets the dose directly in milligrams, and that figure is the dose of each one of the two peptides; there is nothing to mix and nothing to prepare beforehand. That single reading is the practical reason why those who are comparing several cohorts opt for the pen format.

For the breakdown of the compounds taken separately, see BPC-157 vs. TB-500: recovery peptide comparison. For protocol planning once the combination has been chosen, see How to dose BPC-157 + TB-500.

MOTS-c: a peptide for mitochondrial recovery (research overview)

MOTS-c is a 16-amino-acid peptide that is encoded in the mitochondria, within the 12S rRNA region of mitochondrial DNA. It is relevant to recovery research because it regulates nuclear gene expression in response to metabolic stress, rather than acting on local tissue-repair pathways in the way the others do [14]. That mechanism places it in a different category from BPC-157, TB-500 and GHK-Cu, all of which target angiogenesis and cytoprotection at the site of injury.

The key points that are worth knowing before you design a protocol with MOTS-c:

• Mechanism: under metabolic stress, MOTS-c translocates to the nucleus and modulates AMPK-coupled gene expression, which controls glucose handling and mitochondrial biogenesis [9][14].
• Main research variables: exercise-induced fatigue, insulin sensitivity and metabolic recovery after sustained physical exertion, as established by the 2021 mouse and human work by Reynolds et al. (Lee's group) in Nature Communications [13].
• Not a GH-axis peptide: MOTS-c does not signal through the GHRH or ghrelin receptors, so it does not overlap mechanistically with CJC-1295 or ipamorelin and should not be used as a substitute for them in GH-axis studies [9].
• Evidence base: smaller than that of BPC-157; Reynolds et al. 2021 remains the foundational human reference and, as of 2026, no large-scale independent phase II/III replication of it has been published [13].

Where MOTS-c fits in a recovery research stack

MOTS-c is best classed as a candidate for systemic metabolic recovery rather than as a structural-repair peptide. What that means in practice is that it complements BPC-157 + TB-500 in models of post-exertion mitochondrial fatigue, rather than replacing them. Body Pharm supplies MOTS-c in the same pre-filled multi-dose pen format as the BPC-157 + TB-500 combination pen: the dose is set in milligrams on the dial, and it is the same across every cohort and every administration within a given study arm.

CJC-1295 + Ipamorelin: GH-axis recovery research

CJC-1295 + ipamorelin is a paired GH-axis research combination: CJC-1295 is a GHRH analogue that prolongs the GHRH signal by means of its DAC (Drug Affinity Complex) modification, while ipamorelin triggers a clean pulse of GH through its selective agonist activity at GHS-R (the growth hormone secretagogue receptor) [7][15]. The combination is studied for synergistic GH secretion, which in preclinical models is relevant to anabolic signalling, deep-sleep architecture and post-training recovery [7].

Mechanistic split: why the combination exists

CJC-1295 with DAC binds to serum albumin and extends its half-life into the 6-to-8-day range that is described in the foundational 2006 pharmacokinetic study by Teichman et al. in the Journal of Clinical Endocrinology & Metabolism; that study remains the main pharmacokinetic reference in 2026, because between 2024 and 2026 no human pharmacokinetic study has been published that would supersede it [7]. Ipamorelin is a selective GHS-R agonist which, in preclinical work, produces GH release without the rise in cortisol or prolactin that is associated with the older secretagogues such as GHRP-6 [15].

Evidence base and regulatory position

Human study data on the specific CJC-1295 + ipamorelin combination remain limited in the indexed literature from 2024 to 2026; most of the recent commentary centres on stacking strategies rather than on any new pharmacodynamic measurements [7]. Neither of the two peptides is an authorised medicinal product, and both of them are treated as investigational substances. On top of that, both of them fall, in competition, within WADA's prohibited class of peptide hormones and growth factors [3].

Body Pharm's 20 mg combination pen

Body Pharm supplies CJC-1295 + ipamorelin as a single pre-filled multi-dose pen of 20 mg in total for subcutaneous research injection: the two peptides are co-dissolved 50/50 in the same cartridge and a single dial sets the dose of each in milligrams. There are not two separate pens and there is nothing to combine yourself. Because it carries CJC-1295 in its DAC form, the reference scheme is a single daily dose taken in the evening. Those who are comparing GH-axis signalling with structural-repair pathways usually run this combination alongside a parallel BPC-157 + TB-500 arm; see BPC-157 vs. TB-500: recovery peptide comparison for the structural-repair comparison and How to dose BPC-157 + TB-500 for the parallel dosing scheme.

GHK-Cu and NAD+: complementary recovery pathways

GHK-Cu (copper peptide) and NAD+ (nicotinamide adenine dinucleotide) are the two recovery compounds that are most often used as adjuncts, because each of them addresses a pathway that the four main peptides do not fully cover: extracellular-matrix remodelling and collagen synthesis in the case of GHK-Cu, and intracellular redox balance and DNA repair in the case of NAD+. In 2026 both of them are treated as research substances, and neither one is authorised as an injectable medicinal product [10].

GHK-Cu (copper tripeptide)

GHK-Cu is a glycyl-L-histidyl-L-lysine tripeptide bound to copper(II) that has been studied ever since the 1970s for its effect on the synthesis of collagen and glycosaminoglycans, on anti-inflammatory signalling and on wound-bed remodelling [8]. The 2018 review by Pickart and Margolina in International Journal of Molecular Sciences remains the most cited mechanistic summary, and the secondary literature from 2024 to 2026 has not replaced it with an update of comparable scope [8]. In the EU, GHK-Cu is known above all as a cosmetic ingredient for topical application; injectable GHK-Cu is not an authorised medicinal product, and suppliers provide it exclusively for laboratory research [10].

NAD+ (nicotinamide adenine dinucleotide)

NAD+ is a coenzyme rather than a peptide, but it is routinely studied alongside the recovery peptides because it sits upstream of sirtuin activity, of PARP-mediated (poly-ADP-ribose polymerase) DNA repair and of the mitochondrial electron transport chain. The tissue concentration of NAD+ declines with age, a finding that is set out in Verdin's 2015 review in Science; the reviews on mitochondrial peptides from 2024 to 2026 repeatedly pair NAD+ precursors with MOTS-c when they model mitochondrial recovery [6].

Those who are comparing the copper peptide's effects on the extracellular matrix (ECM) with the structural-repair arm of BPC-157/TB-500 usually refer back to BPC-157 vs. TB-500: recovery peptide comparison, and anyone setting up a parallel dosing scheme uses How to dose BPC-157 + TB-500 as the template for the protocol. Body Pharm supplies both GHK-Cu and NAD+ in pre-filled multi-dose pens whose dial sets the dose in milligrams, so that the figure recorded is the same across every arm of the study.

How Body Pharm sources and validates recovery peptides

Body Pharm supplies recovery peptides as sealed, pre-filled, validated-dose multi-dose pens, shipped discreetly within Spain and exclusively for laboratory research. Validated dose means that every single pen is checked before release so that the figure set on the dial corresponds to the mass of peptide actually delivered, so that anyone comparing study arms (for example, BPC-157 against the BPC-157 + TB-500 combination) records the same dose across all of them. In 2026, Body Pharm Spain is the official source in Spain for Body Pharm's peptide products.

What "validated dose" means in practice

Our pens are filled and sealed at manufacture and are tracked batch by batch from synthesis right through to shipping. Because they arrive ready to use, the figure you set on the dial is directly the mass of peptide in milligrams: there is no intermediate step of any kind to interpret. This matters especially in the case of peptides where the literature on the pharmacodynamics of the combination is thin, such as the BPC-157 + TB-500 combination, for which, as of 2026, there are no published controlled studies of the combination at all [5].

Regulatory positioning

All Body Pharm products are supplied exclusively for research and analytical purposes. They are not intended for human consumption, they are not authorised medicinal products and they carry no therapeutic claims of any kind, which is exactly how suppliers of the research peptides BPC-157, TB-500, MOTS-c, GHK-Cu and CJC-1295/ipamorelin have to position themselves in 2026 [10].

Those who are moving from comparison on to protocol usually go from BPC-157 vs. TB-500: recovery peptide comparison on to How to dose BPC-157 + TB-500.

Regulatory context: research peptides in 2026

In 2026, none of the peptides covered in this guide is a medicinal product that is authorised for human use. They are lawfully supplied only for in vitro and laboratory research, which is the position that suppliers of research peptides have to adopt in order not to make the kind of claims that belong to a medicinal product [10].

The details matter when it comes to compliance documentation:

• BPC-157 and TB-500 are unauthorised investigational substances, with no approved indications and no completed phase II/III human studies in musculoskeletal conditions as of 2026 [2][5].
• MOTS-c is not authorised; the foundational human data remain those of Reynolds et al. 2021 in Nature Communications, still not replicated in large independent cohorts [13].
• CJC-1295 and ipamorelin are not authorised and, where they do reach clinical use at all, they are obtained through specialist clinics or through individual imports, not as authorised products [10].
• GHK-Cu is known in the EU as a topically applied cosmetic ingredient; injectable GHK-Cu is not an authorised medicinal product [10].
• NAD+ appears in some oral formulations as a food-supplement ingredient, but research suppliers provide it as a research compound, not as a medicinal product.

BPC-157, TB-500, CJC-1295 and ipamorelin appear on the WADA Prohibited List (BPC-157 in section S0, non-approved substances; the other three in section S2, peptide hormones and growth factors); GHK-Cu, NAD+ and MOTS-c are not expressly named on it [3].

This section does not constitute legal advice. Researchers, institutional buyers and clinical staff should consult a qualified regulatory or legal professional about their own specific use, above all if the research moves in the direction of human use or of competitive sport. For a mechanism-level comparison before any purchasing decision, see BPC-157 vs. TB-500: recovery peptide comparison.

Frequently Asked Questions: recovery peptides

Q1: Which is the best peptide for tendon and ligament repair research?

BPC-157 is the most cited peptide in research on tendon and ligament repair, because the rodent models of Achilles tendon and medial collateral ligament transection from the 2010s show accelerated fibroblast migration and accelerated collagen organisation, even though, as of 2026, there are still no completed phase II/III human studies in musculoskeletal conditions [1][2]. It is frequently combined with TB-500 to provide systemic angiogenic support; see How to dose BPC-157 + TB-500.

Q2: What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid gastric pentadecapeptide that acts locally on the VEGFR2 and nitric oxide pathways, while TB-500 is a synthetic fragment of thymosin β4 that acts systemically through actin sequestration and angiogenesis [4][11]. BPC-157 acts more quickly in local injury models; TB-500 has a longer functional half-life. The full comparison of mechanisms is in BPC-157 vs. TB-500: recovery peptide comparison.

Q3: Can MOTS-c be combined with BPC-157 in research?

MOTS-c can be administered alongside BPC-157 in research protocols, because the two of them act on pathways that do not overlap with one another: MOTS-c targets mitochondrial AMPK signalling according to Lee et al. 2015 in Cell Metabolism [9], while BPC-157 targets local angiogenesis and cytoprotection [2]. As of 2026 no published study of the combination existed, so any co-administration is hypothesis-driven and has not been validated.

Q4: What does "validated-dose multi-dose pen" mean?

It is a pre-filled pen with a 3 ml cartridge whose dial sets the dose directly in milligrams, verified at the point of manufacture: if you set 0.25 mg, then 0.25 mg is what gets delivered, and that is exactly what goes into the log. It arrives ready to use, so there is no prior calculation and no preparation step along the way in which accuracy could be lost.

Q5: Why combine CJC-1295 with ipamorelin in recovery research?

CJC-1295 is combined with ipamorelin because CJC-1295 (a GHRH analogue with DAC) maintains the basal GHRH tone, while ipamorelin (a selective GHS-R agonist) triggers, in preclinical models, a discrete pulse of GH without raising either cortisol or prolactin [7][15]. The combination is studied for an enhanced pulsatile release of GH/IGF-1, which is relevant to the recovery variables in question [7].

Q6: Is it legal to buy recovery peptides in Spain?

Recovery peptides such as BPC-157, TB-500, MOTS-c, CJC-1295 and ipamorelin can only be supplied as research chemicals for in vitro or laboratory use, because none of them is an authorised medicinal product [10]. Selling them for human use is not permitted, and BPC-157, TB-500, CJC-1295 and ipamorelin appear on the WADA Prohibited List [3].

Next steps

To map a peptide to your specific repair variable before you buy anything, start with the mechanism comparison in BPC-157 vs. TB-500: recovery peptide comparison, then move on to How to dose BPC-157 + TB-500 in order to build the protocol, and finally order the corresponding validated-dose multi-dose pen from Body Pharm, with shipping within Spain.

Sources

1. Krivic A, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006. pubmed.ncbi.nlm.nih.gov/16583442
2. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. pubmed.ncbi.nlm.nih.gov/40756949
3. World Anti-Doping Agency, Prohibited List of substances and methods (current). wada-ama.org
4. Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. pubmed.ncbi.nlm.nih.gov/22074294
5. ClinicalTrials.gov, searches for "BPC 157" and "thymosin beta 4", consulted in October 2026: no controlled human trial of the BPC-157 + TB-500 combination registered or published. clinicaltrials.gov
6. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015. pubmed.ncbi.nlm.nih.gov/26785480
7. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. pubmed.ncbi.nlm.nih.gov/16352683
8. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018. pubmed.ncbi.nlm.nih.gov/29986520
9. Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metab. 2015. pubmed.ncbi.nlm.nih.gov/25738459
10. Directive 2001/83/EC, Article 1: definition of a medicinal product by presentation and by function; consolidated text on EUR-Lex. eur-lex.europa.eu — legal basis for a reagent labelled "research use only" remaining subject to pharmaceutical regulation if it is presented for human use.
11. Sikiric P, et al. Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Curr Pharm Des. 2018. pubmed.ncbi.nlm.nih.gov/29879879
12. Goldstein AL, Kleinman HK. Advances in the basic and clinical applications of thymosin β4. Expert Opin Biol Ther. 2015. pubmed.ncbi.nlm.nih.gov/26096726
13. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. pubmed.ncbi.nlm.nih.gov/33473109
14. Kim KH, et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018. pubmed.ncbi.nlm.nih.gov/29983246
15. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. pubmed.ncbi.nlm.nih.gov/9849822